1. INTENDED USE

The SDMA Rapid Test is a fluorescence-based immunoassay designed for the quantitative measurement of Symmetric Dimethylarginine (SDMA) in canine and feline serum or plasma. This test provides veterinarians with an essential tool to:

• Detect early renal dysfunction (SDMA rises earlier than creatinine in chronic kidney disease).
• Monitor kidney disease progression and treatment efficacy.
• Assess renal health in aging pets or breeds predisposed to kidney conditions.

Note: For veterinary diagnostic use only. An important adjunct to traditional renal biomarkers.

2. TEST PRINCIPLE

The test utilizes a competitive fluorescence immunoassay methodology:

1. Sample Incubation: SDMA in the sample competes with fluorescently labeled SDMA tracer for binding sites on anti-SDMA antibodies immobilized on the test strip.
2. Fluorescence Measurement: Bound tracer generates a signal inversely proportional to SDMA concentration (higher SDMA = lower fluorescence).
3. Precision Analysis: A dedicated reader quantifies SDMA levels within 10-15 minutes with a sensitive detection range of 2-100 μg/dL.

Key Features:

• Early Biomarker: Detects ~40% renal function loss vs creatinine’s ~75% threshold.
• Species-Specific: Validated for both dogs and cats with ≤5% cross-reactivity to ADMA.
• Stable Performance: Fluorescent labels provide superior stability vs enzymatic methods.

For optimal results: Use fresh samples, avoid hemolysis, and calibrate reader per manufacturer guidelines.